Novo Nordisk Balance Sheet Health
Financial Health criteria checks 4/6
Novo Nordisk has a total shareholder equity of DKK106.6B and total debt of DKK21.3B, which brings its debt-to-equity ratio to 20%. Its total assets and total liabilities are DKK314.5B and DKK207.9B respectively. Novo Nordisk's EBIT is DKK104.0B making its interest coverage ratio -197.3. It has cash and short-term investments of DKK30.2B.
Key information
20.0%
Debt to equity ratio
kr.21.28b
Debt
| Interest coverage ratio | -197.3x |
| Cash | kr.30.23b |
| Equity | kr.106.56b |
| Total liabilities | kr.207.93b |
| Total assets | kr.314.49b |
Recent financial health updates
No updates
Recent updates
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23Novo Nordisk: Dominating In Diabetes And Obesity
Jun 05Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity
May 23Novo Nordisk: Attractive Market But Likely No Margin Of Safety
Feb 15Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg
Feb 07Novo Nordisk FY 2022 Earnings Preview
Jan 31Novo Nordisk says FDA updated label for oral diabetes therapy Rybelsus
Jan 13Financial Position Analysis
Short Term Liabilities: NVO's short term assets (DKK139.6B) do not cover its short term liabilities (DKK169.7B).
Long Term Liabilities: NVO's short term assets (DKK139.6B) exceed its long term liabilities (DKK38.3B).
Debt to Equity History and Analysis
Debt Level: NVO has more cash than its total debt.
Reducing Debt: NVO's debt to equity ratio has increased from 1% to 20% over the past 5 years.
Debt Coverage: NVO's debt is well covered by operating cash flow (511.8%).
Interest Coverage: NVO earns more interest than it pays, so coverage of interest payments is not a concern.